Fig. 6From: Network pharmacology and experimental verification-based strategy for exploring the mechanisms of luteolin in the treatment of osteosarcomaThe integrated pathways map of luteolin in OS setting. (A) The PI3K-AKT signaling pathway. (B) The IL17 signaling pathway. (C) The TNF signaling pathway. The common targets of luteolin and OS were marked in pink and core targets were marked in redBack to article page